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ABSTRACT 
INTRODUCTION: Predicting suboptimal primary debulking and perioperative 
complications will lead to improved outcomes for patients with advanced 
ovarian, fallopian tube, and peritoneal cancer. 
MANUSCRIPT I: A multicenter prospective trial evaluating the ability of 
preoperative computed tomography (CT) scan and serum CA-125 to predict 
suboptimal cytoreduction at primary debulking surgery for advanced ovarian, 
fallopian tube, and peritoneal cancer 
OBJECTIVE: To assess the ability of preoperative CT scan and CA-125 to 
predict suboptimal (>1cm residual disease) primary cytoreduction in advanced 
ovarian, fallopian tube, and peritoneal cancer. 
METHODS: This was a prospective multicenter trial of patients who underwent 
primary cytoreduction for stage III-IV ovarian, fallopian tube, and peritoneal 
cancer. A CT scan of the abdomen/pelvis and serum CA-125 were obtained 
within 35 and 14 days before surgery, respectively. Four clinical and 20 
radiologic criteria were assessed.  
RESULTS: From 7/2001–12/2012, 350 patients met eligibility criteria. The 
optimal debulking rate was 75%. On multivariate analysis, three clinical and six 
radiologic criteria were significantly associated with suboptimal debulking: age 
≥60 years (p=0.01); CA-125 ≥500 U/mL (p<0.001); ASA 3-4 (p<0.001); 
suprarenal retroperitoneal lymph nodes >1cm (p<0.001); diffuse small bowel 
adhesions/thickening (p<0.001); and lesions >1cm in the small bowel 
mesentery (p=0.03), root of the superior mesenteric artery (p=0.003), 
perisplenic area (p<0.001), and lesser sac (p<0.001). A ‘predictive value score’ 
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was assigned for each criterion, and the suboptimal debulking rates of patients 
who had a total score of 0, 1-2, 3-4, 5-6, 7-8, and ≥9 were 5%, 10%, 17%, 
34%, 52%, and 74%, respectively. A prognostic model combining these nine 
factors had a predictive accuracy of 0.758. 
CONCLUSIONS: We identified nine criteria associated with suboptimal 
debulking, and developed a model that was predictive of suboptimal 
cytoreduction. These results may be helpful in pretreatment patient 
assessment. 
 
MANUSCRIPT II: Predictive value of the age-adjusted charlson comorbidity 
index on perioperative complications and survival in patients undergoing 
primary debulking surgery for advanced epithelial ovarian cancer  
OBJECTIVE: To assess the ability of the age-adjusted Charlson comorbidity 
index (ACCI) to predict perioperative complications and survival in patients 
undergoing primary debulking surgery for advanced epithelial ovarian cancer 
(EOC). 
METHODS: Data were analyzed for all patients with stage IIIB-IV EOC who 
underwent primary cytoreduction from 1/2001–1/2010 at our institution. 
Patients were divided into 3 groups based on an ACCI of 0-1, 2-3, and ≥4. 
Clinical and survival outcomes were assessed and compared.  
RESULTS: We identified 567 patients; 199 (35%) had an ACCI of 0-1, 271 
(48%) had an ACCI of 2-3, and 97 (17%) had an ACCI of ≥4. The ACCI was 
significantly associated with the rate of complete gross resection (0-1=44%, 2-
3=32%, and ≥4=32%; p=0.02), but was not associated with the rate of minor 
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(47% vs 47% vs 43%, p=0.84) or major (18% vs 19% vs 16%, p=0.8) 
complications. The ACCI was also significantly associated with progression-
free (PFS) and overall survival (OS). Median PFS for patients with an ACCI of 
0-1, 2-3, and ≥4 was 20.3m, 16m, and 15.4m, respectively (p=0.02). Median 
OS for patients with an ACCI of 0-1, 2-3, and ≥4 was 65.3m, 49.9m, and 
42.3m, respectively (p<0.001). On multivariate analysis, the ACCI remained a 
significant prognostic factor for both PFS (p=0.02) and OS (p<0.001). 
CONCLUSIONS: The ACCI was not associated with perioperative 
complications in patients undergoing primary cytoreduction for advanced EOC, 
but was a significant predictor of PFS and OS. Prospective clinical trials in 
ovarian cancer should consider stratifying for an age-comorbidity covariate.  
OVERALL CONCLUSIONS:  Nine criteria associated with suboptimal 
cytoreduction were identified, and a model that was predictive of suboptimal 
debulking was developed. The ACCI was not associated with perioperative 
complications, but was a significant prognostic factor for survival outcomes.
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ABSTRACT 
OBJECTIVE: To assess the ability of preoperative computed tomography (CT) 
scan of the abdomen/pelvis and serum CA-125 to predict suboptimal (>1cm 
residual disease) primary cytoreduction in advanced ovarian, fallopian tube, 
and peritoneal cancer. 
METHODS: This was a prospective, non-randomized, multicenter trial of 
patients who underwent primary cytoreduction for stage III-IV ovarian, fallopian 
tube, and peritoneal cancer. A CT scan of the abdomen/pelvis and serum CA-
125 were obtained within 35 and 14 days before surgery, respectively. Four 
clinical and 20 radiologic criteria were assessed.  
RESULTS: From 7/2001–12/2012, 669 patients were enrolled; 350 met 
eligibility criteria. The optimal debulking rate was 75%. On multivariate 
analysis, three clinical and six radiologic criteria were significantly associated 
with suboptimal debulking: age ≥60 years (p=0.01); CA-125 ≥500 U/mL 
(p<0.001); ASA 3-4 (p<0.001); suprarenal retroperitoneal lymph nodes >1cm 
(p<0.001); diffuse small bowel adhesions/thickening (p<0.001); and lesions 
>1cm in the small bowel mesentery (p=0.03), root of the superior mesenteric 
artery (p=0.003), perisplenic area (p<0.001), and lesser sac (p<0.001). A 
‘predictive value score’ was assigned for each criterion, and the suboptimal 
debulking rates of patients who had a total score of 0, 1-2, 3-4, 5-6, 7-8, and 
≥9 were 5%, 10%, 17%, 34%, 52%, and 74%, respectively. A prognostic 
model combining these nine factors had a predictive accuracy of 0.758. 
CONCLUSIONS: We identified nine criteria associated with suboptimal 
cytoreduction, and developed a predictive model in which the suboptimal rate 
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was directly proportional to a predictive value score. These results may be 
helpful in pretreatment patient assessment. 
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Introduction 
Of the estimated 21,980 women diagnosed each year with primary 
ovarian, fallopian tube, or peritoneal carcinoma in the United States, the 
majority present with advanced-stage disease [1]. Standard initial therapy for 
these patients consists of primary cytoreductive surgery, or ‘debulking,’ 
followed by platinum and taxane-based chemotherapy [2].  
Numerous studies have demonstrated a survival advantage for patients 
who undergo ‘optimal’ vs ‘suboptimal’ debulking [3-6]. Although various cutoff 
points have been used to define optimal debulking (residual disease ranging 
from 0 to 3cm), the Gynecologic Oncology Group (GOG) currently uses 1cm 
as a cutoff [2]. While previously only of prognostic value, this stratification led 
to significant treatment implications with the publication of GOG–172, a 
randomized trial in women with optimally debulked (≤1cm residual) ovarian 
cancer that showed a significant survival advantage for patients who received 
intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel compared to 
those who received intravenous paclitaxel and cisplatin chemotherapy [7]. 
Intraperitoneal chemotherapy is currently not a treatment option for 
suboptimally debulked women. It is also important to note that for patients who 
are suboptimally cytoreduced (>1cm residual), survival is equivalent 
regardless of residual tumor size [8,9]. Reported rates of optimal cytoreduction 
vary widely in the literature, from 15% to 85% [10]. Therefore it appears that a 
significant proportion of women with advanced ovarian cancer will undergo a 
debulking procedure with associated morbidity but without a commensurate 
improvement in survival.   
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In order to determine which patients would be less likely to benefit from 
primary surgery, several attempts have been made to predict cytoreductive 
outcome, using imaging modalities, tumor markers, and laparoscopic scores 
[11]. Investigators have evaluated the utility of preoperative computed 
tomography (CT) scan in an effort to identify radiologic predictors, with 
inconsistent results [12-16]. The use of preoperative CA-125 has also been 
evaluated in this setting, with a cutoff value of 500 U/mL used by most 
researchers. Some studies have found CA-125 to be significantly associated 
with cytoreductive outcome, while others have not [17-23]. Studies attempting 
to identify preoperative predictors have been limited by their retrospective 
design, sample size, broad inclusion criteria, and heterogeneous rates of 
optimal cytoreduction. The objective of this trial was to prospectively assess 
the ability of preoperative CT scan of the abdomen/pelvis and serum CA-125 
to predict suboptimal primary cytoreduction in patients with advanced epithelial 
ovarian, fallopian tube, and peritoneal cancer. 
Methods 
Patient Eligibility  
This was a prospective, non-randomized, multicenter clinical trial 
approved by the institutional review boards of each institution. All patients ≥18 
years of age with presumed advanced (International Federation of Gynecology 
and Obstetrics [FIGO] stage III-IV) epithelial ovarian, fallopian tube, and 
peritoneal cancer who were assessed by an attending gynecologic oncologist 
for cytoreductive surgery were eligible. A CT scan of the abdomen/pelvis with 
intravenous and oral contrast and serum CA-125 were obtained within 35 and 
14 days before surgery, respectively. Informed consent was obtained from all 
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enrolled patients. This occurred at the initial outpatient visit, before the CT 
scans were evaluated by a protocol radiologist, and before patients’ scheduled 
surgeries. Demographic data were recorded, along with cytoreductive outcome 
and histologic confirmation of diagnosis postoperatively. Suboptimal 
cytoreduction was defined as >1cm residual disease, as classified by the 
GOG. Patients were excluded if they did not have ovarian, fallopian tube, or 
peritoneal cancer; if they did not have advanced disease; or if they received 
neoadjuvant chemotherapy (this was at the discretion of the primary surgeon, 
usually due to findings on a CT scan that was done in-house, or after in-house 
radiologic review of outside CT imaging, both of which occurred after the initial 
visit). Additionally, patients were also excluded if there was significant delay in 
surgery after CT scan (>35 days) or serum CA-125 (>14 days), or if the CT 
scan was of poor quality, lacking contrast, or not assessed by a protocol 
radiologist. Patients with carcinosarcoma, mesothelioma, and mucinous 
histologies were also excluded, as were patients with germ cell, sex-cord 
stromal cell, low-malignant potential, and benign tumors.  
CT scan and Clinical Criteria 
 CT scans were performed after administration of intravenous and oral 
contrast; contiguous slices were acquired, with slice thicknesses ranging from 
5 to 7.5 mm. CT scans performed at outside institutions were included in the 
study only if judged to be of acceptable quality by the study radiologists. Five 
protocol radiologists, all experienced in body CT, analyzed and interpreted the 
images before surgery. They recorded the presence or absence of 20 
radiologic criteria, including: lesions in the porta hepatis, intersegmental fissure 
of the liver, gallbladder fossa, gastrohepatic ligament, lesser sac, root of the 
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superior mesenteric artery (SMA), small bowel mesentery, omentum, liver 
(perihepatic, subcapsular, and intraparenchymal individually), spleen 
(perisplenic and intraparenchymal individually), pulmonary bases, pleural 
bases, and retroperitoneal lymph nodes above the renal hilum (including 
supradiaphragmatic). Other criteria included tumor invading the anterior 
abdominal wall, presacral extraperitoneal disease, the presence of ascites 
(graded as mild, moderate, or severe), and diffuse small bowel 
adhesions/thickening. The latter was interpreted radiologically as angulated 
bowel loops in the presence of small bowel wall thickening. Thickening was 
subjectively assessed by the radiologists with no specific measurement of 
bowel wall thickness used, as it was dependent on the caliber of that loop of 
bowel. Pelvic disease involving the adnexae, uterus, and rectosigmoid colon 
was not assessed as part of this study, as it is generally resectable and does 
not usually affect cytoreductive status.  
Quantitative bi-dimensional measurements were determined for all 
visualized lesions. Qualitative analysis (QA) was performed by using the 
following five-point scale to categorize the degree of radiologic certainty that a 
lesion identified on CT represented a metastatic neoplasm: 1=definitely 
normal; 2=probably normal; 3=indeterminate; 4=probably metastatic; and 
5=definitely metastatic. There were no specific criteria for assigning a QA 
score; scores were determined by the radiologists based on their judgment, 
experience, and the characteristics of the lesions (i.e., solid vs cystic, well 
defined vs poorly defined). In addition to the CT criteria, four clinical criteria 
were considered as potential predictors of cytoreductive outcome: serum CA-
125, age, stage, and American Society of Anesthesiologists (ASA) class as 
determined by the anesthesia team.  
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Statistical Analysis 
Sample size was calculated as follows: a previous study from our 
institution suggested that a cutoff value for the preoperative serum CA-125 
that correctly identified 90% of optimally cytoreduced patients correlated with a 
level that would also correctly identify 40% of suboptimally cytoreduced 
patients [17]. This protocol was designed to test whether the proportion of 
suboptimally debulked women correctly classified by the CA-125 cutoff was 
truly 40% or could be as low as 25%. Similarly, it was designed to test whether 
CT scan findings could correctly classify a desirable proportion of suboptimally 
cytoreduced patients. For a type I error of 5% and 80% power, it was 
estimated that 85 suboptimally debulked patients would be required. At the 
time of protocol design, we assumed an optimal cytoreduction rate of 45% 
based on our institutional data [17]. However, coinciding with the start of 
patient accrual, the rate had increased to greater than 75% following a change 
in surgical paradigm and the incorporation of upper abdominal surgery into the 
primary cytoreductive effort [6]. This prolonged the accrual period for the 
study, as it meant that an estimated 340 women with advanced ovarian cancer 
would need to be included to have 85 suboptimally debulked patients.  
 All 20 radiologic and four clinical criteria were assessed for their 
association with suboptimal debulking. Radiologic criteria were considered 
present if lesions had a QA of 4 or 5 and measured >1cm (measurable lesions 
only). Criteria were considered absent if lesions had a QA of 1-3 (any size), or 
if they had a QA of 4 or 5 and measured ≤1cm. Several cutoffs were assessed 
for age, and the cutoff most predictive of suboptimal debulking was used to 
group patients. Due to the small number of patients with an ASA class of 1 and 
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4, patients with an ASA of 3 or 4 were combined and compared to those who 
had an ASA of 1 or 2. A receiver operating characteristic (ROC) curve was 
generated with the data from the current study, and the most predictive cutoff 
value of CA-125 was determined to be 500 U/mL, which is consistent with 
previously published reports [17,21-23]. Associations between the criteria and 
debulking outcome were tested using Fisher’s exact test for categorical 
variables and the Wilcoxon Rank-Sum test for continuous variables. 
Generalized estimating equations were used to account for differences 
between the two institution-clusters, assuming independent covariance 
structure. Based on the results of univariate analysis, backward selection was 
utilized to build a multivariate model predictive of suboptimal cytoreduction, for 
which an ROC curve was generated. The radiologic and clinical criteria found 
to be significant on multivariate analysis were then each assigned a ‘predictive 
value score’ according to their odds ratios (OR). Subsequently, the total 
predictive value score of all patients in the cohort was calculated using their 
radiologic and clinical findings, and the suboptimal debulking rate 
corresponding to each total score was determined. All statistical tests were 
two-sided, and a p value of <0.05 was considered significant. The multivariate 
model was considered exploratory; therefore, no formal adjustment for multiple 
comparisons was made. Statistical analysis was performed using SAS 
statistical software 9.2 (SAS Institute, Cary, NC) and R (R development core 
team, 2013). 
Results 
From July 2001 to December 2012, 669 patients were enrolled, and 350 
met all eligibility criteria. A CONSORT diagram is shown in Figure 1. Two 
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hundred sixty-eight (76%) of the eligible patients were enrolled at the primary 
study institution. The optimal debulking rate was 75% (261 patients). Patient 
and tumor characteristics are shown in Table 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: CONSORT diagram of all enrolled patients. CT, computed 
tomography; IV, intravenous. 
 
Enrolled patients 
(N = 669) 
Excluded (n = 319) 
 
Non-ovarian, fallopian tube, or peritoneal cancer (n = 55) 
Stage I-II cancer (n = 54) 
Histologic reasons 
  Carcinosarcoma (n = 13) 
  Mesothelioma (n = 2) 
  Mucinous (n = 4) 
  Germ cell (n = 2) 
  Sex-cord stromal cell (n = 2) 
  Low malignant potential (n = 6) 
  Benign (n = 22) 
Received neoadjuvant chemotherapy (n =  48) 
CT or CA-125 not done within required time limit (n = 30) 
CT inevaluable or not assessed by protocol radiologist (n = 57) 
Patient withdrawal (n = 24) 
 
Eligible patients 
(n = 350) 
Optimally debulked 
(n = 261) 
Suboptimally debulked 
(n = 89) 
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Table 1: Patient and Tumor Characteristics (N = 350) 
Variable n (%) 
Age (years) 
Median (range) 
 
61 (34 – 86) 
Primary site of disease 
Ovary 
Fallopian tube 
Peritoneal 
 
264 (75%) 
42 (12%) 
44 (13%) 
FIGO Stage 
III A/B 
IIIC 
IV 
 
8 (2%) 
248 (71%) 
94 (27%) 
Grade 
1 
2 
3 
N/A 
 
11 (3%) 
8 (2%) 
328 (94%) 
3 (1%) 
Histology 
Serous 
Endometrioid/Clear cell 
Mixed/Other 
 
314 (90%) 
2 (0.6%) 
34 (10%) 
Preoperative CA-125 (U/mL) 
Median (range) 
 
860 (9 – 38,100) 
ASA class 
1 
2 
3 
4 
N/A 
 
10 (3%) 
158 (45%) 
178 (51%) 
3 (1%) 
1 (0.3%) 
 
FIGO, International Federation of Gynecology and Obstetrics; ASA, 
American Society of Anesthesiologists 
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On univariate analysis, three clinical and 12 radiologic criteria were found 
to be significantly associated with suboptimal cytoreduction (Tables 2 and 3). 
Seventy-one percent (63/89) of suboptimally debulked patients had a CA-125 
≥500 U/mL and 41% (106/261) of optimally debulked patients had a CA-125 
<500 U/mL. Due to the small number of suboptimally debulked women whose 
CT scans showed liver intraparenchymal lesions, spleen intraparenchymal 
lesions, and presacral extraperitoneal disease (<5 patients each), these 
criteria were excluded from further analysis. 
On multivariate analysis, after backward selection, three clinical and six 
radiologic criteria remained significant: age ≥60 years (OR 1.32, p=0.01); CA-
125 ≥500 U/mL (OR 1.47, p<0.001); ASA 3-4 (OR 3.23, p<0.001); 
retroperitoneal lymph nodes above the renal hilum (including 
supradiaphragmatic) >1cm (OR 1.59, p<0.001); diffuse small bowel 
adhesions/thickening (OR 1.87, p<0.001); small bowel mesentery lesions 
>1cm (OR 2.28, p=0.03); root of the SMA lesions >1cm (OR 2.4, p=0.003); 
perisplenic lesions >1cm  (OR 2.27, p<0.001); and lesser sac lesions >1cm 
(OR 4.61, p<0.001) (Table 4). ROC curves were generated, with a predictive 
model utilizing the six CT criteria showing an area under the curve (AUC) of 
0.688. The six CT criteria and the preoperative CA-125 combined had an AUC 
of 0.696. The most accurate model combined the six CT criteria, CA-125, age, 
and ASA, demonstrating an AUC of 0.758 (Figure 2).  
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Table 2: Clinical Criteria – Univariate Analysis 
Criteria Suboptimal Rate OR 95% CI p  
Age  
≥ 60 years 
< 60 years 
 
53/187 (28%) 
36/163 (22%) 
1.4 1.39 - 1.4 <0.001 
CA-125  
≥ 500 U/mL 
< 500 U/mL 
 
63/218 (29%) 
26/132 (20%) 
1.66 1.31 - 2.1 <0.001 
ASA 
3-4 
1-2 
 
61/181 (34%) 
28/168 (17%) 
2.54 1.4 - 4.6 0.002 
Stage 
IV 
III 
 
26/94 (28%) 
63/256 (25%) 
1.17 0.75 - 1.84 0.49 
 
ASA, American Society of Anesthesiologists 
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Table 3: Radiologic Criteria – Univariate Analysis 
 
 
Criteria 
Suboptimal Rate 
 
 
OR 
 
 
95% CI 
 
 
p  Criteria 
Present  
Criteria 
Absent  
Porta hepatis  
lesion >1 cm 
18/50 
(36%) 
71/300 
(24%) 
1.81 1.53 - 2.15 <0.001 
Liver intersegmental 
fissure lesion >1cm 
14/48 
(29%) 
75/302 
(25%) 
1.25 0.64 - 2.41 0.51 
Gallbladder fossa 
lesion >1 cm 
9/25 
(36%) 
80/325 
(25%) 
1.72 1.29 - 2.31 <0.001 
Gastrohepatic 
ligament lesion  
>1 cm 
22/38 
(58%) 
67/312 
(21%) 
5.03 2.07 - 12.23 <0.001 
Lesser sac lesion  
>1 cm 
20/35 
(57%) 
69/315 
(22%) 
4.75 4.38 - 5.16 <0.001 
Root of the superior 
mesenteric artery 
lesion >1 cm 
5/8 
(63%) 
84/342 
(25%) 
5.12 4.23 - 6.2 <0.001 
Small bowel 
mesentery 
lesion >1 cm 
27/61 
(44%) 
62/289 
(21%) 
2.91 1.53 - 5.51 <0.001 
Retroperitoneal 
lymph nodes above 
the renal hilum 
(including 
supradiaphragmatic) 
>1 cm 
26/72 
(36%) 
63/278 
(23%) 
1.93 1.72 - 2.17 <0.001 
Omental lesion 
 >1 cm 
52/212 
(25%) 
37/138 
(27%) 
0.89 0.61 - 1.29 0.53 
Perihepatic lesion   
>1 cm 
24/95 
(25%) 
65/255 
(25%) 
0.99 0.58 - 1.68 0.97 
18 
 
Subcapsular liver 
lesion >1 cm 
10/44 
(23%) 
79/306 
(26%) 
0.85 0.63 - 1.13 0.26 
Liver 
intraparenchymal 
lesion >1 cm 
4/9 
(44%) 
85/341 
(25%) 
2.41 1.87 - 3.11 <0.001 
Perisplenic lesion  
>1 cm 
26/59 
(44%) 
63/291 
(22%) 
2.85 2.27 - 3.58 <0.001 
Spleen 
intraparenchymal  
lesion >1 cm 
3/7 
(43%) 
86/343 
(25%) 
2.24 1.29 - 3.89 0.004 
Tumor invading 
anterior abdominal 
wall >1 cm 
3/11 
(27%) 
86/339 
(25%) 
1.1 0.9 - 1.35 0.34 
Presacral 
extraperitoneal 
disease >1 cm 
2/4 
(50%) 
87/346 
(25%) 
2.98  2 - 4.44 <0.001 
Diffuse small bowel 
adhesions/ 
thickening 
9/24 
(38%) 
80/326 
(25%) 
1.85 1.78 - 1.91 <0.001 
Abdominal ascites 
(moderate-severe) 
48/154 
(31%) 
41/196 
(21%) 
1.71 1.11 - 2.65 0.02 
Pulmonary 
metastasis (lung 
bases) 
3/13 
(23%) 
86/337 
(26%) 
0.88 0.66 - 1.15 0.34 
Pleural metastasis  
(lung bases) 
4/17 
(24%) 
85/333 
(26%) 
0.9 0.6 - 1.34 0.59 
 
All measurable lesions had a QA of 4 or 5 
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Table 4: Multivariate Model of Significant Clinical and Radiologic Criteria 
Predictive of Suboptimal Cytoreduction 
 
Criteria OR 95% CI p  
Predictive 
Value 
Score 
Age ≥60 years 1.32 1.06 - 1.63 0.01 1 
CA-125  ≥500 U/mL 1.47 1.28 - 1.69 <0.001 1 
ASA 3-4  3.23 1.76 - 5.91 <0.001 3 
Retroperitoneal lymph 
nodes above the renal 
hilum (including 
supradiaphragmatic)   
>1 cm 
1.59 1.58 - 1.6 <0.001 1 
Diffuse small bowel 
adhesions/ thickening 
1.87 1.86 - 1.87 <0.001 1 
Perisplenic lesion >1 cm 2.27  1.7 - 3.03 <0.001 2 
Small bowel mesentery 
lesion >1 cm 
2.28 1.08 - 4.8 0.03 2 
Root of the superior 
mesenteric artery lesion 
>1 cm 
2.4 1.34 - 4.32 0.003 2 
Lesser sac lesion >1 cm 4.61 4.39 - 4.84 <0.001 4 
 
ASA, American Society of Anesthesiologists 
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Figure 2: Receiver operating characteristic curve showing correlation 
between the nine predictive criteria and suboptimal 
cytoreduction. AUC: area under the curve. 
 
To add clinical utility to our findings, we assigned a ‘predictive value 
score’ for the nine criteria significant on multivariate analysis, which was based 
on their multivariate ORs. Age ≥60 years, CA-125 ≥500 U/mL, retroperitoneal 
lymph nodes above the renal hilum (including supradiaphragmatic) >1cm, and 
diffuse small bowel adhesions/thickening were each assigned a predictive 
value score of 1. Perisplenic lesions >1cm, small bowel mesentery lesions 
>1cm, and root of the SMA lesions >1cm were each assigned a score of 2. 
ASA 3-4 was assigned a score of 3, and lesser sac lesions >1cm were 
assigned a score of 4 (Table 4). We then calculated the total predictive value 
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score of all patients in our cohort using their clinical and CT scan findings, and 
determined the suboptimal debulking rate corresponding to each total score. 
The rate was linearly correlated to the predictive value score. Patients who 
had a score of 0 (none of the criteria present) had a suboptimal rate of 5%. 
The suboptimal rates of patients who had a score of 1-2, 3-4, 5-6, and 7-8 
were 10%, 17%, 34%, and 52%, respectively. The highest suboptimal rate, 
74%, was for patients who had a score of 9 or greater (Table 5).  
 
Table 5: Predictive Value Score and Suboptimal Cytoreduction (N = 349) 
 
Total Predictive 
Value Score 
Total Patients  
n (%) 
Optimal 
(n) 
Suboptimal 
(n) 
Suboptimal 
Rate 
0 22/349 (6%)  21 1 5% 
1 - 2 79/349 (23%)  71 8 10% 
3 - 4 109/349 (31%)  91 18 17% 
5 - 6 85/349 (24%)  56 29 34% 
7 - 8 31/349 (9%)  15 16 52% 
≥ 9 23/349 (7%)  6 17 74% 
 
*1 patient excluded for a missing American Society of Anesthesiologists class 
 
Discussion 
In two high-volume ovarian cancer centers, we identified three clinical 
and six radiologic criteria associated with suboptimal cytoreduction and 
developed a predictive model in which the suboptimal rate was directly 
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proportional to a predictive value score. This model had an overall predictive 
accuracy of 0.758.  
Previous investigators assessing the utility of preoperative CT scan in this 
setting have retrospectively identified different radiologic predictors [12-16]. 
Axtell et al.’s analysis of 65 patients showed diaphragm disease and large 
bowel mesentery implants to be significant factors [15]. Dowdy et al.’s review 
of 89 patients found diffuse peritoneal thickening to be the only variable 
significantly associated with suboptimal debulking [16]. In our analysis, three 
out of the six predictive radiologic criteria involved the small bowel, which 
makes intuitive and physiologic sense. The incorporation of advanced surgical 
techniques and the ability to resect upper abdominal disease (splenic, 
perihepatic, etc) has led to higher optimal debulking rates [6,24]. However, 
there is a limit to how much small bowel and/or mesentery can be resected 
without compromising essential function. Therefore, extensive disease 
involving the majority of the small bowel mesentery and serosa is anecdotally 
cited by expert surgeons as the most common factor precluding optimal 
debulking.  
Chi and colleagues initially reported that a preoperative serum CA-125 
>500 U/mL was significantly associated with suboptimal debulking [17]. A 
follow-up study demonstrated that while the CA-125 was a predictor of upper 
abdominal disease, it was not necessarily associated with suboptimal 
cytoreduction if extensive upper abdominal procedures were incorporated into 
the surgical approach [21]. Other reports have shown conflicting results, and a 
recent meta-analysis concluded that although a CA-125 >500 U/mL was a 
strong risk factor for suboptimal debulking, it lacked the accuracy to 
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independently predict surgical outcome [18-20,22,23]. In our study, a CA-125 
value ≥500 U/mL was a statistically significant predictive factor and was the 
best cutoff based on ROC curve evaluation (not shown). However, it is 
important to note that it has limited clinical utility on its own, as 29% of patients 
with a value ≥500 U/mL were suboptimally debulked, compared to 20% of 
those with a value <500 U/mL. We consequently feel that the preoperative CA-
125 level should be used in combination with the other criteria to guide clinical 
management.  
Regarding our model design, which was exploratory, we assigned equal 
weights to all the criteria in our initial analysis (not shown) and then calculated 
the suboptimal rate based solely on the number of criteria present. The rate 
increased proportionally to the number of criteria. However, our data revealed 
that certain factors were more predictive than others (for example, lesser sac 
lesions >1cm had an OR of 4.61, while age ≥60 years had an OR of 1.32). The 
final model was therefore based on weighted criteria with a predictive value 
score assigned, as this was considered a more accurate way to model the 
actual effects. In addition, in the model, lesser sac lesions >1cm had a 
predictive value score of 4, significantly higher than other criteria. The 35 
patients who had lesser sac lesions >1cm had a median predictive value score 
of 8, with a range of 4 to 12. This suggests that in patients with carcinoma that 
is extensive enough to involve the lesser sac, the disease has likely spread to 
several other anatomic locations as well.   
While previous studies have assessed the utility of preoperative CT scan 
in predicting outcome, they were limited by their retrospective nature, small 
sample size, inclusion of early-stage disease, and variable rates of optimal 
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cytoreduction (49% to 78%) [12-16]. Our study’s strength lies in its prospective 
design; the CT scans were evaluated by a dedicated group of radiologists prior 
to patients’ surgeries, thereby guaranteeing their blinding with regard to 
surgical outcomes and findings. We also had a large patient cohort, with 350 
women included. The study was carried out in two institutions, which increases 
the external validity of our analysis. The two institutions are tertiary cancer 
centers with a high rate of optimal debulking (75%), and only patients with 
advanced-stage cancer were included. In our model, we were able to combine 
the predictive value of radiologic criteria with that of clinical criteria. This not 
only takes into account patients’ extent of disease but also their overall 
medical status and ability to undergo general anesthesia and extensive 
surgery. We feel the inclusion of clinical factors increases the strength of our 
model, as age and medical status are critical factors in the complex decision-
making process for gynecologic oncologists when determining if a patient is a 
candidate for primary debulking, as opposed to neoadjuvant chemotherapy. 
Although a patient’s disease sites may render her amenable for optimal 
resection based on a surgeon’s technical ability and surgical armamentarium, 
one with a poor overall medical condition may not be able to tolerate the 
prolonged complicated procedure often necessary to achieve optimal 
debulking [25].  
The main limitation of our trial is the study period needed to accrue the 
required number of suboptimally cytoreduced patients, as CT imaging 
technology and surgical practice may have changed over time. Surgeons were 
aware of preoperative CT findings, as being blinded to the imaging would have 
been detrimental to patient care. While this can be seen as a potential bias, it 
is essential to note that all six CT criteria that were significantly associated with 
25 
 
suboptimal debulking in our study only came to light when the data was 
analyzed and the multivariate model built, which occurred after the trial was 
closed to accrual. Therefore, despite knowledge of patients’ preoperative 
imaging, surgeons were not aware which of these findings would ultimately be 
associated with suboptimal cytoreduction. Selection bias is another potential 
limitation, as 48 patients who received neoadjuvant chemotherapy were 
excluded. This was at the discretion of the attending gynecologic oncologist, 
who upon reviewing CT imaging after the initial visit, deemed certain patients 
to not be amenable for optimal primary cytoreduction. This was a subjective 
assessment based on each surgeon’s own experience, judgment, and 
technical abilities, with no specific criteria employed. These patients did not 
undergo an attempt at primary debulking, and it is possible that some may 
have been optimally cytoreduced. Nonetheless, had these patients undergone 
primary surgery, it is possible that additional imaging criteria may have been 
significantly associated with cytoreductive outcome. With regards to the 
evaluation of imaging, the QA scale used to assess the lesions, while 
described before [26], has not been validated, and is admittedly used in an 
attempt to objectively quantify subjective findings. In addition, each CT scan 
was read by one protocol radiologist. As such, the reproducibility of the 
findings and interobserver variability were not assessed. We also have not 
validated our scoring system in another population at this time.  
The GOG definition of optimal debulking uses 1cm as a cutoff [2]. 
However, several studies have shown a survival advantage for patients with 
no gross residual compared to those with ≤1cm gross residual [5,9,27]. Based 
on that data, many gynecologic oncologists currently feel that the goal of 
primary cytoreduction for ovarian cancer should be complete gross resection 
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to no gross residual. Nevertheless, our trial was designed to assess 
preoperative predictors based on a definition of optimal debulking that uses a 
1cm cutoff. We therefore did not feel it would be statistically valid to report 
outcomes based on a changed endpoint. One can hypothesize that if 
preoperative findings suggest that a gross residual of ≤1cm cannot be 
achieved, then the same findings would imply that cytoreduction to no residual 
disease is unlikely. As this assertion cannot be formally supported with the 
current analysis, we plan on addressing this question with a secondary 
analysis of our data in the future. It is important to note however that even if 
the goal of cytoreduction is complete gross resection, that may not necessarily 
align with the goal of predicting surgical outcome; as there may still be a 
potential survival benefit for patients with ≤1cm but grossly visible disease 
after primary debulking, compared to those who are treated with neoadjuvant 
chemotherapy [9,27,28,29,30,31]. 
In our predictive model, the suboptimal debulking rate increased 
progressively from 5% to 74% based on the predictive value score. With 
further validation, these results may be helpful in pretreatment patient 
assessment and counseling, and in guiding clinical management. At this time, 
we do not advocate a certain cutoff rate above which neoadjuvant 
chemotherapy should be administered to a patient. We feel it is reasonable for 
each individual surgeon and center to determine what threshold to use; based 
on their own experience, outcomes, treatment philosophy, and ability to 
employ extensive surgical techniques in order to achieve optimal 
cytoreduction.  
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Chapter 1 has been published as a peer-reviewed manuscript in Gynecologic 
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Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Mironov S, Iyer RB, et al. 
A multicenter prospective trial evaluating the ability of preoperative computed 
tomography scan and serum CA-125 to predict suboptimal cytoreduction at 
primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal 
cancer. Gynecol Oncol 2014;134:455–61. 
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ABSTRACT 
OBJECTIVE:  To assess the ability of the age-adjusted Charlson comorbidity 
index to predict perioperative complications and survival in patients 
undergoing primary debulking surgery for advanced epithelial ovarian cancer 
(EOC). 
METHODS: Data were analyzed for all patients with stage IIIB-IV EOC who 
underwent primary cytoreduction from 1/2001–1/2010 at our institution. 
Patients were divided into 3 groups based on an age-adjusted Charlson 
comorbidity index of 0-1, 2-3, and ≥4. Clinical and survival outcomes were 
assessed and compared.  
RESULTS: We identified 567 patients; 199 (35%) had an age-adjusted 
Charlson comorbidity index of 0-1, 271 (48%) had an index of 2-3, and 97 
(17%) had an index of ≥4. The index was significantly associated with the rate 
of complete gross resection (0-1=44%, 2-3=32%, and ≥4=32%; p=0.02), but 
was not associated with the rate of minor (47% vs 47% vs 43%, p=0.84) or 
major (18% vs 19% vs 16%, p=0.8) complications. The index was also 
significantly associated with progression-free (PFS) and overall survival (OS). 
Median PFS for patients with an index score of 0-1, 2-3, and ≥4 was 20.3m, 
16m, and 15.4m, respectively (p=0.02). Median OS for patients with an index 
score of 0-1, 2-3, and ≥4 was 65.3m, 49.9m, and 42.3m, respectively 
(p<0.001). On multivariate analysis, the index remained a significant 
prognostic factor for both PFS (p=0.02) and OS (p<0.001). 
CONCLUSIONS: The age-adjusted Charlson comorbidity index was not 
associated with perioperative complications in patients undergoing primary 
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cytoreduction for advanced EOC, but was a significant predictor of PFS and 
OS. Prospective clinical trials in ovarian cancer should consider stratifying for 
an age-comorbidity covariate.  
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Introduction 
Of the estimated 21,290 women diagnosed each year with epithelial 
ovarian, fallopian tube, or peritoneal carcinoma in the United States, the 
majority present with advanced-stage (International Federation of Gynecology 
and Obstetrics [FIGO] III/IV) disease [1]. Standard therapy for these patients 
consists of primary debulking surgery, followed by adjuvant chemotherapy [2]. 
Numerous studies have shown a survival advantage for patients who undergo 
‘optimal’ vs ‘suboptimal’ cytoreduction [3][4].  
In order to achieve optimal surgical outcomes, primary debulking surgery 
is frequently lengthy and complex, requiring bowel resection and/or aggressive 
upper abdominal surgery [5]. Such extensive procedures are commonly 
associated with significant perioperative complications [6][7][8][9][10][11]. 
Given this risk, neoadjuvant chemotherapy followed by interval debulking is 
offered by certain providers to patients who are poor operative candidates due 
to age and/or medical comorbidity [12][13][14][15]. However, this is subjective 
and surgeon dependent, and no consensus exists on which comorbid 
conditions or age render a patient a poor operative candidate.  
 The Charlson comorbidity index is a prognostic index that was developed 
to predict 1-year mortality based on medical comorbidity [16]. It is a score 
derived by the summation of the weighted scores of 19 medical conditions 
found to be associated with survival, and has been validated in several 
populations [17][18][19]. Age was subsequently found to be predictive of death 
from comorbid disease by the authors. It was incorporated to create a 
combined score accounting for both comorbidity and age, the age-adjusted 
Charlson comorbidity index, which has been validated as well [20].  
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Researchers have attempted to predict morbidity or survival in this patient 
population using a variety of prognostic factors and models 
[13][14][21][22][23][24][25][26]. However, limited data exists assessing the 
prognostic significance of a validated comorbidity index on these outcomes. 
The objective of our study was to assess the ability of the age-adjusted 
Charlson comorbidity index to predict perioperative complications and survival 
in patients undergoing primary debulking surgery for advanced epithelial 
ovarian, fallopian tube, and peritoneal cancer. 
Methods 
After obtaining institutional review board approval, we identified all 
patients with FIGO stage IIIB-IV epithelial ovarian, fallopian tube, and 
peritoneal cancer who underwent primary cytoreduction at our institution from 
January 2001 to January 2010. Patients were excluded if they had non-
epithelial ovarian cancer, tumors of low-malignant potential, or if they received 
neoadjuvant chemotherapy. Clinical data, perioperative complications, and 
survival outcomes were retrospectively reviewed from the medical records. 
Data abstracted included: age, medical comorbidity, body mass index, primary 
disease site, FIGO stage, histology, tumor grade, preoperative albumin, 
preoperative platelet count, preoperative CA-125, presence and amount of 
ascites at surgery, presence of gross residual disease after cytoreductive 
surgery, and intraperitoneal chemotherapy administration. 
The age-adjusted Charlson comorbidity index was assigned to all 
patients using their individual medical conditions and age at the time of 
primary debulking. The scoring system as described by Charlson et al. is 
shown in Table 6 [20]. The overall score is calculated based on the total of 
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each patient’s comorbid conditions (which are weighted according to severity) 
and age. As all patients had advanced ovarian cancer, that condition was 
excluded from the scoring system. Patients were categorized into three groups 
based on an age-adjusted comorbidity index score of 0-1 (low), 2-3 
(intermediate), and ≥4 (high).  
 
Table 6: Age-adjusted charlson comorbidity index (N = 567) 
 
 
Score 
 
 
Comorbidity 
 
n (%) 
1 Diabetes mellitus without end-organ damage  27 (5%) 
Cerebrovascular disease  10 (2%) 
Myocardial infarction 14 (2%) 
Congestive heart failure 0 (0%) 
Peripheral vascular disease  9 (2%) 
Dementia 2 (0.4%) 
Chronic pulmonary disease 55 (10%) 
Connective tissue disease 37 (7%) 
Peptic ulcer disease  16 (3%) 
Mild liver disease  5 (1%) 
2 Diabetes mellitus with end-organ damage 2 (0.4%) 
Moderate/severe renal disease 0 (0%) 
Hemiplegia  0 (0%) 
Solid tumor without metastasis  
(exclude if >5 years from diagnosis) 
32 (6%) 
Leukemia 2 (0.4%) 
Lymphoma 9 (2%) 
3 Moderate/severe liver disease  0 (0%) 
6 Metastatic solid tumor 0 (0%) 
AIDS (not just HIV positive) 0 (0%) 
 
Age adjustment: For each decade after 40 years, add 1 point to total score 
(i.e. 1 point for age group 50-59 years, 2 points for age group 60-69, etc) 
AIDS, Acquired immune deficiency syndrome; HIV, Human 
immunodeficiency virus  
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In 2001, our institution established a prospectively maintained adverse 
events database of all surgical cases. Data on perioperative complications at 
up to 30 days postoperatively is collected for all patients. Complications are 
graded for severity on a scale of 1-5 using a standardized institutional grading 
system: 1 = use of oral medications and/or bedside intervention to treat an 
event; 2 = use of intravenous medications, parenteral nutrition, enteral 
nutrition, or blood transfusion to treat an event; 3 = interventional radiology, 
therapeutic endoscopy, intubation, or operation required to treat an event; 4 = 
residual and lasting disability requiring major rehabilitation or organ resection; 
and 5 = event resulting in death of patient [27]. This grading system has been 
validated, with Grade 1-2 complications considered minor and Grade 3-5 
complications considered major [28]. Complications are also classified by 
system, including but not limited to gastrointestinal, cardiac, pulmonary, and 
neurologic systems. 
 The three age-adjusted index groups were assessed for their association 
with Grade 1-2 (minor) and Grade 3 (major) perioperative complications. As 
only one patient each had a Grade 4 or 5 complication, those grades were not 
included in any analysis. Given that the complexity and number of procedures 
during primary debulking is correlated with the rate and severity of surgical 
complications [6][22], we stratified our cohort into three subgroups according 
to a validated surgical complexity score [22][29]. As described by Aletti and 
colleagues, that score is calculated based on the specific procedures 
performed in a cytoreductive case, and classifies surgeries as having low, 
intermediate, and high complexity. We then performed a secondary analysis, 
assessing the association between the age-adjusted index and complications 
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within those subgroups. The age-adjusted index was also evaluated for its 
ability to predict specific systems-based complications. 
Progression-free survival (PFS) and overall survival (OS) were additional 
endpoints in our study. The date of progression was determined by computed 
tomography (CT) scan and/or CA-125 levels. When determined by CT scan, 
the progression date was taken as the first appearance of one or more new 
lesions or increased size of existing lesions. When determined by CA-125 
level, the progression date was defined as the first date of the initial CA-125 of 
greater than or equal to two times the nadir value or upper limit of normal, as 
applicable [30][31]. When a subsequent CT scan confirmed that the rise in CA-
125 indicated progression, the progression date was defined as the date of 
CA-125 rise. PFS was defined as the time interval from the date of primary 
debulking to the date of disease progression, death, or last follow-up. OS was 
defined as the time interval from the date of surgery to the date of death or last 
follow-up. 
Categorical variables were compared using the χ2 test, and continuous 
variables were compared using the Kruskal-Wallis test. All statistical tests 
were two-sided, with a p of <0.05 considered significant. When testing the 
association between the age-adjusted index and specific systems-based 
complications, logistic regression analysis was performed adjusting for surgical 
complexity. The Kaplan–Meier method was used to estimate survival rates. 
Univariate analysis of all assessed categorical and continuous variables was 
performed for prognostic significance using the log-rank test and Cox 
proportional hazards model for significance, respectively. Differences in 
survival were calculated using the Cox proportional hazards model. Variables 
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with a p of <0.05 on univariate analysis were then included in a multivariate 
Cox regression analysis. Statistical analysis was performed using SPSS 22.0 
(IBM Corporation, Armonk, NY). 
Results 
Five hundred and sixty-seven patients were included over the study 
period. One hundred and ninety-nine patients (35%) had an age-adjusted 
Charlson comorbidity index score of 0-1, two hundred and seventy-one 
patients (48%) had an index score of 2-3, and 97 patients (17%) had an index 
score of ≥4. The most common comorbid conditions were ‘chronic pulmonary 
disease’ (n = 55, 10%), ‘connective tissue disease’ (n = 37, 7%), ‘other solid 
tumors’ (n = 32, 6%), and ‘diabetes mellitus’ (n = 27, 5%) (Table 6). Patient 
and tumor characteristics are shown in Table 7. The high index group (≥4) had 
the highest median age, while the low index group (0-1) had the highest 
proportion of patients with Stage IV disease and the highest median 
preoperative platelet count. The age-adjusted index was significantly 
associated with both the rate of optimal debulking (≤1 cm residual disease) 
(p=0.01) and the rate of complete gross resection (p=0.02).  
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Table 7: Patient and tumor characteristics (N = 567) 
 
Characteristic 
 
ACCI 0-1 
(Low) 
 
n = 199 (35%) 
ACCI 2-3 
(Intermediate) 
 
n = 271 (48%) 
ACCI ≥4 
(High) 
 
n = 97 (17%) 
p 
Median age 
(range) 
51 years 
(23 – 59) 
65 years 
(43 – 79) 
74 years 
(60 – 96) 
<0.001 
Median Body 
mass index 
(range) 
 
25.2 kg/m2 
(16.3 – 43.7) 
 
25.7 kg/m2 
(17.6 – 54.6) 
 
25 kg/m2 
(18.3 – 50.1) 
0.49 
FIGO Stage 
IIIB 
IIIC 
IV 
 
10 (5%) 
148 (74%) 
41 (21%) 
 
8 (3%) 
226 (83%) 
37 (14%) 
 
5 (5%) 
86 (89%) 
6 (6%) 
 
0.01 
Primary disease 
site 
Ovary 
Fallopian tube 
Peritoneum 
 
167 (84%) 
16 (8%) 
16 (8%) 
 
204 (75%) 
28 (10%) 
39 (15%) 
 
74 (76%) 
9 (9%) 
14 (15%) 
 
0.19 
Histology 
Serous 
Endometrioid 
Clear cell 
Mixed/Other 
 
181 (91%) 
1 (1%) 
2 (1%) 
15 (8%) 
 
249 (92%) 
2 (1%) 
0 (0%) 
20 (7%) 
 
81 (84%) 
2 (2%) 
0 (0%) 
14 (14%) 
 
0.1 
Tumor grade  
1 
2 
3 
 
8 (4%) 
16 (8%) 
175 (88%) 
 
7 (3%) 
14 (5%) 
250 (92%) 
 
3 (3%) 
5 (5%) 
89 (92%) 
 
0.6 
Median 
preoperative  
albumin (range) * 
4.1 g/dL 
(2.5 – 4.8) 
4.1 g/dL 
(2.1 – 5) 
4.1 g/dL 
(2.4 – 4.8) 
0.97 
Median 
preoperative  
platelet count 
(range)  
367 K/µl 
 (204 – 1067) 
366 K/µl 
(175 – 920) 
314 K/µl 
(113 – 1067) 
<0.001 
Median 
preoperative  
CA-125 (range) † 
681 U/mL 
(3 – 28,503) 
496 U/mL 
(3 – 38,100) 
444 U/mL 
(9 – 24,500) 
 
 
0.05 
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Ascites 
None 
1 – 1000 
1001 – 5000 
>5000 
 
50 (25%) 
57 (29%) 
73 (37%) 
19 (9%) 
 
74 (27%) 
71 (26%) 
92 (34%) 
34 (13%) 
 
38 (39%) 
24 (25%) 
31 (32%) 
4 (4%) 
 
0.09 
Residual disease 
None  
≤1 cm 
>1 cm 
 
87 (44%) 
77 (39%) 
35 (17%) 
 
86 (32%) 
107 (39%) 
78 (29%) 
 
31 (33%) 
37 (38%) 
29 (30%) 
 
0.02 
Intraperitoneal 
chemotherapy  
administration  
(optimally 
debulked 
patients  
2005 – 2010) 
64/101 
(63%) 
60/124 
(48%) 
20/36 
(56%) 
0.08 
 
ACCI: Age-adjusted charlson comorbidity index 
Data missing for: * eight, and † twenty four patients.  
 
 Among the entire cohort, two hundred and sixty-one patients (46%) had a 
Grade 1-2 (minor) complication, and 101 patients (18%) had a Grade 3 (major) 
complication. One patient with an index score of 1 had a Grade 4 complication, 
and one patient with an index score of 4 had a Grade 5 complication. The age-
adjusted index was not associated with the overall rate of Grade 1-2 or Grade 
3 complications. For patients with an age-adjusted index of 0-1, 2-3, and ≥4, 
the overall rate of Grade 1-2 complications was 47% (n = 93/199), 47% (n = 
126/271), and 43% (n = 42/97) respectively (p=0.84). Similarly, the overall rate 
of Grade 3 complications was 18% (n = 36/199), 19% (n = 50/271), and 16% 
(n = 15/97) respectively (p=0.8).  
 As the extent of a debulking procedure is related to perioperative 
complications, we stratified our cohort into three subgroups based on a 
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surgical complexity score [29]. One hundred and fifty patients (27%) had a 
surgery of low complexity, two hundred and fifty-five patients (45%) had a 
surgery of intermediate complexity, and 162 patients (29%) had a surgery of 
high complexity (Table 8). After this stratification, the age-adjusted index was 
still not associated with the overall rate of Grade 1-2 or Grade 3 complications. 
 
Table 8: Age-adjusted charlson comorbidity index and perioperative 
complications based on surgical complexity  
 
 
Surgical  
Complexity  
Score* 
 
ACCI 
 
Patients 
n (%) 
 
 
Grade 1-2 
(Minor) 
Complications 
n (%) 
 
 
p  
 
Grade 3 
(Major) 
Complications 
n (%) 
 
 
p 
 
≤3 
 
0 – 1 40 
(27%) 
21/40 (52%) 0.64 6/40 (15%) 0.29 
2 – 3 70 
(46%) 
35/70 (50%) 6/70 (9%) 
≥4  40 
(27%) 
17/40 (43%) 2/40 (5%) 
 
4 – 7 
 
0 – 1 104 
(41%) 
48/104 (46%) 0.61 11/104 (11%) 0.49 
2 – 3 112 
(44%) 
56/112 (50%) 14/112 (13%) 
≥4  39 
(15%) 
16/39 (41%) 7/39 (18%) 
 
≥8  
 
0 – 1 55 
(34%) 
24/55 (44%) 0.67 19/55 (35%) 0.99 
2 – 3 89 
(55%) 
35/89 (39%) 30/89 (34%) 
≥4  18 
(11%) 
9/18 (50%) 6/18 (33%) 
 
ACCI: Age-adjusted charlson comorbidity index 
* Higher score denotes higher surgical complexity 
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The most common complications were gastrointestinal (n = 146, 26%), 
followed by wound (n = 131, 23%), infectious (n = 116, 21%), and pulmonary 
complications (n = 90, 16%) (Table 9). Among the 12 different system-based 
complications, the age-adjusted index was only significantly associated with 
cardiovascular complications on univariate analysis: the rate was 3% (n = 
6/199), 5% (n = 13/271), and 10% (n = 10/97) for patients with an age-
adjusted index of 0-1, 2-3, and ≥4 respectively (p=0.03). However, after 
adjusting for surgical complexity on logistic regression analysis, that difference 
was no longer significant (p=0.06).  
 
Table 9: Age-adjusted charlson comorbidity index and complication type  
(N = 567) 
 
 
Complication 
Type 
 
 
Total 
Patients 
 
n (%) 
 
 
ACCI 0-1 
 
 
n = 199 
(35%) 
 
ACCI 2-3 
 
 
n = 271 
(48%) 
 
ACCI ≥4 
 
 
n = 97 
(17%) 
 
p  
 
Adjusted 
p* 
Infectious 116  
(21%) 
43 
(22%) 
55 
(20%) 
18 
(19%) 
0.83 0.88 
Venous  
thromboembolism 
76 
(13%) 
18 
(9%) 
44 
(16%) 
14 
(14%) 
0.07 0.1 
Hematologic  
 
72 
(13%) 
21 
(11%) 
41 
(15%) 
10 
(10%) 
0.25 0.47 
Gastrointestinal 146 
(26%) 
52 
(26%) 
77 
(28%) 
17 
(18%) 
0.11 0.14 
Genitourinary 46 
(8%) 
16 
(8%) 
23 
(9%) 
7 
(7%) 
0.93 0.99 
Cardiovascular 29 
(5%) 
6 
(3%) 
13 
(5%) 
10 
(10%) 
0.03 0.06 
Pulmonary 90 
(16%) 
35 
(18%) 
42 
(16%) 
13 
(13%) 
0.63 0.59 
Wound 131 
(23%) 
39 
(20%) 
67 
(25%) 
25 
(26%) 
0.34 0.28 
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General 14 
(3%) 
5 
(3%) 
6 
(2%) 
3 
(3%) 
0.89 0.85 
Endocrine 2 
(0.5%) 
0 
(0%) 
2 
(1%) 
0 
(0%) 
0.33 0.99 
Musculoskeletal 1 
(0.2%) 
0 
(0%) 
0 
(0%) 
1 
(1%) 
0.09 0.99 
Neurologic 14 
(3%) 
5 
(3%) 
4 
(2%) 
5 
(5%) 
0.13 0.1 
 
ACCI: Age-adjusted charlson comorbidity index 
* P-value adjusting for surgical complexity score 
 
The median PFS and OS for the entire study population were 17.1 
months (95% CI, 15.7 – 18.5) and 52.1 months (95% CI, 47.6 – 56.6) 
respectively, with a median follow-up of 68.1 months (range, 1 – 147.3) for the 
181 survivors. The age-adjusted index was significantly associated with PFS 
and OS (Table 10). Median PFS for patients who had an index score of 0-1, 2-
3, and ≥4 was 20.3 months,16 months, and 15.4 months, respectively (p=0.02) 
(Figure 3). Median OS for patients who had an index score of 0-1, 2-3, and ≥4 
was 65.3 months, 49.9 months, and 42.3 months, respectively (p<0.001) 
(Figure 4). On multivariate analysis, after adjusting for stage, histology, 
preoperative albumin, ascites volume, residual disease, and intraperitoneal 
chemotherapy administration, both PFS (p=0.02) and OS (p<0.001) remained 
significant. 
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Table 10: Age-adjusted charlson comorbidity index and survival 
 
 
ACCI 
 
PFS 
 
 
95% CI 
 
 
p 
 
Adjusted 
p* 
 
 
OS 
 
 
95% CI 
 
 
p 
 
Adjusted 
p* 
 
0 – 1 
 
 
20.3 
m 
 
16.6 – 
24 
 
 
0.02 
 
 
 
0.02 
 
 
65.3
m 
 
54.7 -
75.8 
 
<0.001 
 
 
 
<0.001 
 
 
2 – 3 
 
 
16 
m 
 
14.5 -
17.6 
 
 
49.9
m 
 
42.9 - 
57 
 
≥4  
 
 
15.4 
m 
 
13 -
17.8 
 
 
42.3
m 
 
29.9 -
54.8 
 
ACCI: Age-adjusted charlson comorbidity index; PFS: Progression-free 
survival; OS: Overall survival; m: months 
* P-value adjusting for stage, histology, preoperative albumin, ascites volume, 
residual disease, and intraperitoneal chemotherapy administration 
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Figure 3: Progression-Free Survival: ACCI 0-1 vs 2-3 vs ≥4 
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Figure 4: Overall Survival: ACCI 0-1 vs 2-3 vs ≥4 
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Discussion 
 In this large institutional cohort of patients undergoing primary 
cytoreduction for advanced epithelial ovarian, fallopian tube, and peritoneal 
cancer, the age-adjusted Charlson comorbidity index was a significant 
predictor of both PFS and OS. It was not associated with minor or major 
perioperative complications.  
 Previous investigators have attempted to predict survival outcomes in 
patients undergoing debulking for ovarian cancer using different prognostic 
criteria and models [13][14] [22][23][25][26]. Few have used a validated 
comorbidity score, and we could not identify any studies that used the age-
adjusted Charlson comorbidity index. Using a Danish cancer registry, Tetsche 
et al. evaluated the original Charlson comorbidity index in patients with Stage 
I-IV disease, and found it to be significantly associated with one and five-year 
survival [25]. Sperling and colleagues also used a Danish national clinical 
database to assess patients with all-stage disease, and reported a significant 
association between the Charlson comorbidity index and OS [26]. Both 
authors acknowledged the limitations of using administrative databases, 
including the potential underreporting of comorbidity and misclassification due 
to reliance on ICD-10 codes. Our study is consistent with those results, but 
differs in several ways. We used a validated index that not only assessed 
comorbidity but also took age into account. This is important as age has been 
found to be an independent prognostic factor for survival [14][32][33]. In 
addition, we only assessed women with advanced-stage disease, a group that 
has significantly worse survival outcomes compared to those with early-stage 
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cancer. We also extracted data directly from medical records, and evaluated 
both PFS and OS.   
 It is interesting to note that more patients in the low index group (0-1) had 
both an optimal debulking outcome and complete gross resection. This 
suggests that physicians may be more likely to subject patients to an extensive 
procedure to achieve those outcomes if those patients are younger and/or 
have less comorbidity. Indeed, patients in the high index group (≥4) comprised 
27% of those with a low surgical complexity, compared to 11% of those with a 
high surgical complexity (Table 8). This is despite the low index group (0-1) 
having more patients with Stage IV disease. That fact also suggests that 
patients with an index of ≥4 who were suspected of having Stage IV disease 
may have been more likely to get neoadjuvant chemotherapy, an outcome not 
assessed in our study. In addition, the age-adjusted index was not associated 
with the rate of intraperitoneal chemotherapy administration when only 
assessing optimally debulked patients. Importantly, the discrepancies 
mentioned did not affect PFS and OS, as the differences in survival persisted 
in a multivariate model adjusting for them.  
 Researchers have also attempted to predict perioperative morbidity in 
patients undergoing primary debulking [14][21][22][24]. As with survival, there 
are few reports of a validated comorbidity score being employed in this setting. 
Using claims data from the Nationwide Inpatient Sample database, Wright et 
al. showed that the Charlson Comorbidity Index was associated with surgical-
site, medical, and infectious complications [21]. The authors recognized that 
not being able to account for the ‘degree’ of cytoreduction was an important 
limitation to their study. On the other hand, our data showed no association 
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between the age-adjusted index and either minor or major perioperative 
complications. Our stratification by surgical complexity is a major strength, as 
the extent of a cytoreductive procedure is correlated with surgical 
complications, especially when upper abdominal procedures are employed 
[6][22]. After this stratification, the age-adjusted index was still not associated 
with either minor or major complications. We also found no association 
between the index and separate systems-based complications. The use of our 
adverse events database for our analysis is another strength, in which 
complications are prospectively reported, classified by system, and graded for 
severity.  
As with our survival analysis, we consider that using a comorbidity index 
that accounts for age to also be an advantage when assessing perioperative 
complications. Many providers prefer to administer neoadjuvant chemotherapy 
for elderly patients, due to a concern for complications and those patients’ 
ability to tolerate them [12][14]. One can hypothesize however, that a healthy 
75 year old woman with no comorbidity may be more likely to tolerate an 
extensive debulking procedure than a 60 year old with significant medical 
conditions. The rates of both minor and major complications were similar in all 
age-adjusted index groups in our data, suggesting that patients who are older 
but have less comorbidity have similar outcomes to those who are younger 
with more medical problems. This might reinforce the case that healthy elderly 
women should not be denied the possible benefits of optimal primary 
debulking and subsequent intraperitoneal therapy based on age alone [14].  
 The main limitation of our study is the retrospective nature of our 
analysis. The age-adjusted index was calculated based on comorbidity 
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reported by patients at the initial visit with the gynecologic oncologist. It is 
possible that some comorbid conditions may have been underreported by 
patients at that visit, or undiagnosed at that time. We addressed this by 
reviewing records from medical clearance notes, outside referring provider 
documentation, and interdisciplinary consultations, with minimal discrepancy 
found. We also did not take into account subsequent medical conditions that 
patients developed during their follow up course, which may have ultimately 
impacted their survival. We chose not to as the main aim of our study was to 
predict perioperative complications and survival based on the age-adjusted 
index at the time of debulking. Despite its validation in numerous populations, 
the use of the age-adjusted comorbidity index has its own limitations. Owing to 
advances in medical treatment of different conditions, the survival impact of 
the comorbid conditions included in its summation may be different today than 
when the index was developed [16][20]. 
 In addition to being a prognostic factor for survival, our results suggest 
that the age-adjusted index may have important implications in ovarian cancer 
research as well. As demonstrated in our data, median PFS decreased from 
20.3 months to 15.4 months for patients who had an ACCI of 0-1 and ≥4, 
respectively. Median OS also decreased from 65.3 months to 42.3 months, 
respectively. Not accounting for these differences in survival, or considering 
age or comorbidity alone when designing a trial may lead to an imbalance of 
patients in different arms, and significant confounding of treatment effects.  
 In conclusion, the age-adjusted Charlson comorbidity index was 
significantly associated with survival outcomes in patients undergoing primary 
debulking for advanced epithelial ovarian, fallopian tube, and peritoneal 
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cancer. It was not predictive of minor or major perioperative complications. 
Further investigation is needed to identify women who are at high risk for 
operative morbidity. Prospective clinical trials in ovarian cancer should 
consider stratifying for an age-comorbidity covariate. 
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